Comparison · NCT01654445-43fc20cf
Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: Number of Patients With Recanalization 4-8 Hours Post-treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: Number of Patients With Recanalization 4-8 Hours Post-treatment. Trial comparisons, record NCT01654445-43fc20cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01654445-43fc20cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.391 | 0.222 | 0.592 | wilson | |
| Risk in group 2 | 0.522 | 0.33 | 0.708 | wilson | |
| Risk difference, group 1 minus group 2 | -0.13 | -0.382 | 0.147 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.394 | 1.43 | log | |
| Odds ratio, group 1 over group 2 | 0.589 | 0.183 | 1.9 | log | |
| Number needed to treat, for one fewer participant with the outcome on Tenecteplase 0.1 mg/kg than on Tenecteplase 0.25 mg/kg | 7.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tenecteplase 0.1 mg/kg | 25 patients treated with 0.1 mg/kg intravenous tenecteplase | 9 | 23 | OG000 |
| Group 2 | Tenecteplase 0.25 mg/kg | 25 patients treated with 0.25 mg/kg intravenous tenecteplase | 12 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Patients With Recanalization 4-8 Hours Post-treatment
- Description
- Recanalization defined on follow-up 4-8 hour CTA as a modified arterial occlusive lesion (mAOL) score 0-1.
- Time frame
- 4-8 hours
- Population
- 2 patients in each tier had missing data on this outcome.
Source ClinicalTrials.gov
Trial
- Title
- TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
- NCT number
- NCT01654445
- Phases
- PHASE2
- Conditions
- Ischemic Stroke
- Interventions
- Tenecteplase
- Lead sponsor
- University of Calgary
- Results first posted
- 2020-11-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01654445?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01654445-43fc20cf